Skip to content
PubMed This is a summary of 71 peer-reviewed journal articles Updated
Allergy and Immunology

The Path to a Clear Diagnosis: Understanding MCAS Criteria

At a Glance

Under the professional-society consensus approach, MCAS diagnosis requires recurrent symptoms in at least two organ systems, a tryptase rise during a flare compared with baseline, and clear improvement with targeted treatment; symptoms alone are not enough.

If you have spent months or even years searching for an answer to a baffling array of symptoms, finding the term Mast Cell Activation Syndrome (MCAS) can feel like finally finding the map to a territory you’ve been lost in for a long time. It is a condition where mast cells—the “alarm system” cells of your immune system—become overactive and release chemicals (mediators) like histamine into your body at the wrong times [1][2].

While the internet is full of stories about MCAS, it is also a source of significant confusion. Because its symptoms—like flushing, racing heart, and digestive issues—overlap with many other conditions, it is frequently both misdiagnosed and over-diagnosed [3][4]. Understanding the strict, professional-society “gold standard” for diagnosis—and how it compares to alternative proposals—can help you navigate your medical journey with clarity and confidence. You can read more about what these symptoms look like in the Signs, Symptoms, and Look-Alikes section.

Diagnostic Criteria: Two Frameworks

Because symptoms can overlap with other conditions [3], accurate diagnosis is important to ensure patients receive the correct treatment. There are currently two principal diagnostic proposals that are commonly discussed [5], which is why it is helpful to ask your doctor which approach they use.

The “Consensus-1” Criteria (Professional Society Standard)
Endorsed by major scientific organizations and professional societies (via the ECNM-AIM international consortium) [6], this framework requires you to meet three strict criteria [1][5]:

  1. Multisystem Symptoms: You must experience typical, recurrent symptoms that affect at least two different organ systems at the same time [1][7]. For example, you might have skin flushing combined with severe abdominal pain or a sudden drop in blood pressure [2][8].
  2. The Tryptase “Rise”: Tryptase is a protein found inside mast cells. When they “fire,” tryptase levels in your blood go up. To meet this criterion, your tryptase must be tested during a flare (within 1–4 hours of symptoms starting) and compared to your normal “baseline” level when you feel fine [1][9]. The level during a flare must be at least 20% higher than your baseline plus an additional 2 ng/mL [1].
  3. Response to Treatment: You must show a clear, measurable improvement in your symptoms when taking medications that target mast cell mediators, such as H1 and H2 antihistamines or mast cell stabilizers [1][10].

The “Consensus-2” Proposal (Alternative Approach)
Supported by a sizable contingent of investigators and practitioners, this broader proposal argues that restrictive criteria underdiagnose patients [11][5]. It requires episodic symptoms and improvement with treatment, but allows for alternative laboratory evidence—such as elevated validated mast-cell mediators in the urine, a tryptase rise above baseline on one occasion, or a persistently high baseline tryptase (though elevated baseline alone does not establish MCAS)—rather than requiring the strict 20% + 2 ng/mL tryptase rise [12][5][6]. Review authors caution that alternative criteria often lack validation and specificity, which may lead to misdiagnosis [13], though proponents argue both approaches are reasonable pending better research [5].

Why Accuracy Matters

Relying on symptoms alone without objective lab evidence is risky [2]. For example, many people with chronic fatigue or unexplained pain are told they have MCAS based on symptoms alone, which may lead doctors to overlook the real cause of their symptoms [2]. For instance, conditions like Hereditary Alpha-Tryptasemia (HaT) (a genetic trait causing high baseline tryptase) or Dysautonomia (problems with the nervous system) can look very similar to MCAS but require different management [14][15].

The Three Types of MCAS

Once a diagnosis is confirmed, doctors look for the underlying “why.” MCAS is generally divided into three categories, which are explored more deeply in The Biology of “Twitchy” Cells.

Type Description
Primary (Monoclonal) Caused by a genetic mutation (often the KIT D816V mutation) in the mast cells themselves, making them inherently hyper-reactive [2][16].
Secondary The mast cells are normal, but they are being “provoked” by another condition, such as a severe allergy, an autoimmune disease, or a chronic infection [2][17].
Idiopathic The criteria for MCAS are met, but doctors cannot find a genetic mutation or an underlying trigger to explain why the cells are misbehaving [2][18].

Understanding these categories is the first step in moving from a state of panic to a state of clinical management. By focusing on objective data, you and your care team can build a treatment plan that is grounded in evidence rather than guesswork.

Common questions in this guide

What criteria are used to diagnose MCAS?
Under the professional-society consensus approach, MCAS requires recurrent symptoms affecting at least two organ systems, an objective rise in tryptase during a flare, and clear improvement with treatment that blocks or stabilizes mast-cell mediators. All three parts are important because symptoms can resemble many other conditions.
How is the 20% + 2 ng/mL tryptase rule calculated?
A blood sample should be collected during a flare, usually within 1–4 hours after symptoms begin, and compared with a baseline sample taken when you feel well. The flare value must reach at least (baseline × 1.2) + 2 ng/mL; a persistently high baseline alone does not meet this criterion.
Can symptoms alone confirm MCAS?
No. Flushing, a fast heartbeat, digestive problems, fatigue, and pain can occur with several conditions, so objective laboratory evidence and a treatment response are important under the consensus approach. Hereditary alpha-tryptasemia, a genetic trait linked to high baseline tryptase, and dysautonomia, a nervous-system disorder, can resemble MCAS but may require different management.
What do primary, secondary, and idiopathic MCAS mean?
Primary, or monoclonal, MCAS is linked to abnormal mast cells, often involving the KIT D816V mutation. Secondary MCAS occurs when another condition, such as severe allergy, autoimmune disease, or chronic infection, provokes otherwise normal mast cells. Idiopathic MCAS meets diagnostic criteria without an identified mutation or underlying trigger.
What if my tryptase does not show the expected rise?
Your clinician may consider other validated mast-cell mediator tests, such as urinary N-methylhistamine or prostaglandin measurements, depending on the clinical situation. Some proposed criteria also consider a one-time tryptase rise or persistently high baseline tryptase, but a high baseline alone does not establish MCAS and these alternatives may be less well validated.
How does treatment response factor into an MCAS diagnosis?
A clear, measurable improvement with medicines that target mast-cell mediators, such as H1 or H2 antihistamines or mast-cell stabilizers, is one part of the consensus diagnostic criteria. Improvement by itself is not enough; it must be considered alongside the symptom pattern and objective mediator testing.

Get notified when new evidence is published on Mast Cell Activation Syndrome (MCAS).

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.

    Matito A, Escribese MM, Longo N, et al.

    Journal of investigational allergology & clinical immunology 2021; (31(6)):461-470 doi:10.18176/jiaci.0675.

    PMID: 33541851
  2. 2

    Idiopathic mast cell activation syndrome is more often suspected than diagnosed-A prospective real-life study.

    Buttgereit T, Gu S, Carneiro-Leão L, et al.

    Allergy 2022; (77(9)):2794-2802 doi:10.1111/all.15304.

    PMID: 35364617
  3. 3

    Mast Cell Activation: When the Whole Is Greater than the Sum of Its Parts.

    Khokhar D, Akin C

    The Medical clinics of North America 2020; (104(1)):177-187 doi:10.1016/j.mcna.2019.09.002.

    PMID: 31757235
  4. 4

    [Idiopathic mast cell activation syndrome].

    van Daele PLA, Hermans MAW, Oude Elberink JHNG, van Wijk RG

    Nederlands tijdschrift voor geneeskunde 2022; (166()).

    PMID: 35129899
  5. 5

    Diagnosis of mast cell activation syndrome: a global "consensus-2".

    Afrin LB, Ackerley MB, Bluestein LS, et al.

    Diagnosis (Berlin, Germany) 2021; (8(2)):137-152 doi:10.1515/dx-2020-0005.

    PMID: 32324159
  6. 6

    Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach.

    Lee E, Picard M

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (21(1)):49 doi:10.1186/s13223-025-00998-9.

    PMID: 41272881
  7. 7

    How to diagnose mast cell activation syndrome: practical considerations.

    Romantowski J, Górska A, Lange M, et al.

    Polish archives of internal medicine 2020; (130(4)):317-323 doi:10.20452/pamw.15212.

    PMID: 32096778
  8. 8

    Recurrent Cyclic Vomiting and Gastroparesis-Like Symptoms in a Patient With Mast Cell Activation Syndrome (MCAS): A Case of Gastrointestinal-Predominant MCAS.

    Salib M, Music A, Salib J, et al.

    Cureus 2026; (18(2)):e103302 doi:10.7759/cureus.103302.

    PMID: 41835650
  9. 9

    [Tryptase: A practical guide for the physician].

    Lobbes H, Reynaud Q, Mainbourg S, et al.

    La Revue de medecine interne 2020; (41(11)):748-755 doi:10.1016/j.revmed.2020.06.006.

    PMID: 32712042
  10. 10

    Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium.

    Valent P, Hartmann K, Bonadonna P, et al.

    The journal of allergy and clinical immunology. In practice 2022; (10(8)):1941-1950 doi:10.1016/j.jaip.2022.05.007.

    PMID: 35623575
  11. 11

    Progress in mast cell activation syndrome: the global consensus-2 diagnostic criteria at six years.

    Afrin LB, Blitshteyn S, Bluestein LS, et al.

    Diagnosis (Berlin, Germany) 2026; doi:10.1515/dx-2026-0016.

    PMID: 42240520
  12. 12

    Mast Cell Activation Syndrome.

    Frieri M

    Clinical reviews in allergy & immunology 2018; (54(3)):353-365 doi:10.1007/s12016-015-8487-6.

    PMID: 25944644
  13. 13

    Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review.

    Gülen T, Akin C, Bonadonna P, et al.

    The journal of allergy and clinical immunology. In practice 2021; (9(11)):3918-3928 doi:10.1016/j.jaip.2021.06.011.

    PMID: 34166845
  14. 14

    Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions.

    Lyons JJ, Greiner G, Hoermann G, Metcalfe DD

    The journal of allergy and clinical immunology. In practice 2022; (10(8)):1964-1973 doi:10.1016/j.jaip.2022.05.003.

    PMID: 35597543
  15. 15

    Dysautonomia, Hypermobility Spectrum Disorders and Mast Cell Activation Syndrome as Migraine Comorbidities.

    Blitshteyn S

    Current neurology and neuroscience reports 2023; (23(11)):769-776 doi:10.1007/s11910-023-01307-w.

    PMID: 37847487
  16. 16

    [Research progress of mast cell activation syndrome].

    Ren HL, Yang YS, Sun JL

    Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2021; (55(12)):1513-1517 doi:10.3760/cma.j.cn112150-20210728-00722.

    PMID: 34963253
  17. 17

    Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026.

    Akin C, Gülen T, Castells MC, et al.

    The journal of allergy and clinical immunology. In practice 2026; (14(1)):19-28 doi:10.1016/j.jaip.2025.10.046.

    PMID: 41285202
  18. 18

    A Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis.

    Gülen T

    Diagnostics (Basel, Switzerland) 2023; (13(21)) doi:10.3390/diagnostics13213307.

    PMID: 37958203

This page is for informational purposes only and does not constitute medical advice. A qualified clinician should interpret your tryptase results, evaluate other possible conditions, and decide whether MCAS testing or treatment is appropriate.